2024 Expert Speakers

Picture of Aaron Koenig, Neuropsychiatric Drug Development

Aaron Koenig

Chief Medical Officer

Delix Therapeutics

Picture of Ariana Mullin, Neuropsychiatric Drug Development

Ariana Mullin

Director - Regulatory Affairs

Bristol Myers Squibb

Ayan Ghoshal

Associate Director & Head of Physiology, Neural Circuits & Pharmacolog

Biogen

Berra Yazar Klosinski, Neuropsychiatric Drug Development

Berra Yazar-Klosinski

Chief Scientific Officer

Lykos Therapeutics

Charmaine Lykins, Neuropsychiatric Drug Development

Charmaine Lykins

Commercial Strategy Advisor

MapLight Therapeutics

Chris Chatham

Consultant

Independent

Connor Maltby, Neuropsychiatric Drug Development

Connor Maltby

Team Leader - Biomarker/Cell Culture

Ulysses Neuroscience

Cornelia Dorner-Ciossek, Neuropsychiatric Drug Development

Cornelia Dorner-Ciossek

Head of Digital Health TA CNS Retinopathies Emerging Areas

Boehringer Ingelheim

Dalibor Sames, Neuropsychiatric Drug Development

Dalibor Sames

Co-Founder, Gilgamesh Pharmaceuticals & Faculty

Columbia University

Daniel Karlin, Neuropsychiatric Drug Development

Daniel Karlin

Chief Medical Officer

MindMed

Dan Smith, Neuropsychiatric Drug Development

Daniel Smith

Executive Director & Head of Translational Medicine

Alkermes

Dilara Bahceci, Neuropsychiatric Drug Development

Dilara Bahceci

Research Fellow

The George Institute

Dina Burkitbayeva, Neuropsychiatric Drug Development

Dina Burkitbayeva

Chief Executive Officer

Freedom Biosciences

Douglas Turk, Neuropsychiatric Drug Development

Douglas Turk

President

Eurofins

Elemer Piros, Neuropsychiatric Drug Development

Elemer Piros

Senior Managing Director

Rodman & Renshaw

Estibaliz Cirauqi, Neuropsychiatric Drug Development

Estibaliz Arce Cirauqui

Vice President - Translational Science & Clinical Development

Engrail Therapeutics

Gabriel Jacobs, Neuropsychiatric Drug Development

Gabriel Jacobs

Research Director - Psychiatry

Center For Human Drug Research

George Papakostas, Neuropsychiatric Drug Development

George Papakostas

CTNI

Massachusetts General Hospital

Gerard Marek, Neuropsychiatric Drug Development

Gerard Marek

Chief Medical Officer

Gilgamesh Pharmaceutical

Greg Ryslik, Neuropsychiatric Drug Development

Gregory Ryslik

Chief Technology Officer

COMPASS Pathways

Guy Goodwin, Neuropsychiatric Drug Development

Guy Goodwin

CMO

COMPASS Pathways

Hadile Ounallah-Saad, Neuropsychiatric Drug Development

Hadile Ounallah Saad

Head of Innovation early stage pipeline

Clexio Biosciences

Harald Murck, Neuropsychiatric Drug Development

Harald Murck

Apl. Professor

Philipps-Universität Marburg

Jackie Von Salm, Neuropsychiatric Drug Development

Jacqueline von Salm

Co-Founder & Chief Scientific Officer

Psilera Bioscience

Joseph Palumbo, Neuropsychiatric Drug Development

Joseph Palumbo

CMO

STALICLA

Katherine Bevans, Neuropsychiatric Drug Development

Katherine Bevans

Director - Patient Reported Outcomes, Neuroscience

Janssen

Kevin Sanders, Neuropsychiatric Drug Development

Kevin Sanders

Executive Medical Director- CNS

Otsuka

Kjartan Herrick, Neuropsychiatric Drug Development

Kjartan Frisch Herrik

Research Fellow

Lundbeck

Kurt Rasmussen, Neuropsychiatric Drug Development

Kurt Rasmussen

Chief Scientific Officer

Delix Therapeutics

Laura Perez Cano, Neuropsychiatric Drug Development

Laura Perez-Cano

Head of Discovery

STALICLA

Linda Carpenter

Deputy Director

Butler COBRE Center for Neuromodulation

Mathieu Grace, Neuropsychiatric Drug Development

Mathieu Grace

Core Lab Expert

BioTrial

Matt Kuntz, Neuropsychiatric Drug Development

Matt Kuntz

Vice President, Global Regulatory

Abbvie

Matt Harlin, Neuropsychiatric Drug Development

Matthew Harlin

Senior Director - Discovery Research & Early Phase , Translational Medicine

Otsuka

Matthew Johnson, Neuropsychiatric Drug Development

Matthew Johnson

Senior Group Leader

The Broad Institute of MIT & Harvard

Michael Halassa, Neuropsychiatric Drug Development

Michael Halassa

Associate Professor - Neuroscience

Tufts University

Michael McCully, Neuropsychiatric Drug Development

Michael McCully

Co-Founder, President & Chief Executive Officer

Gate Neurosciences, Inc.

Murali Gopalakrishnan, Neuropsychiatric Drug Development

Murali Gopalakrishnan

Global Head of Neuroscience Search & Evaluation

Abbvie

Nina Dedic, Neuropsychiatric Drug Development

Nina Dedic

Former Senior Director & Head of Central Nervous System Pharmacology

Sumitomo Pharma America (Formerly)

Patricio O'Donnell, Neuropsychiatric Drug Development

Patricio O’Donnell

Vice President - Translational Medicine

Alto Neuroscience

Shaheen Lakhan, Neuropsychiatric Drug Development

Shaheen Lakhan

Chief Medical Officer

Click Therapeutics

Snezana Milanovic, Neuropsychiatric Drug Development

Snezana Milanovic

Senior Director, TMED & Early Development

Sumitomo Pharma America, Inc.

Steve Brannan, Neuropsychiatric Drug Development

Stephen Brannan

Former Chief Medical Officer

Karuna Therapeutics

Steve Moss, Neuropsychiatric Drug Development

Stephen Moss

Professor - Neuroscience

Tufts University

Steve Kanes

Chief Executive Officer

EmbarkNeuo

Timothy Smith, Neuropsychiatric Drug Development

Timothy Smith

Associate Director of Sales

bit.bio

Umed Boltaev, Neuropsychiatric Drug Development

Umed Boltaev

Associate Research Scientist

Columbia University

Wayne Drevets, Neuropsychiatric Drug Development

Wayne Drevets

Vice President, Disease Area Team Leader, Neuroscience

Johnson & Johnson Services, Inc

2024 EVENT GUIDE
REGISTER INTEREST
PARTNER FOR 2025